thiotepa riemser
esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - agents antinéoplasiques - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.
lanitop 0,1 mg comp.
esteve pharmaceuticals gmbh - métildigoxine 0,1 mg - comprimé - 0,1 mg - métildigoxine 0.1 mg - metildigoxin
triesence 40 mg/ml susp. inj. i.vitr. flac.
novartis pharma sa-nv - acétonide de triamcinolone 40 mg/ml - suspension injectable - 40 mg/ml - acétonide de triamcinolone 40 mg/ml - triamcinolone
triesence 40 mg/ml suspension injectable
novartis pharma schweiz ag - triamcinoloni acetonidum - suspension injectable - triamcinoloni acetonidum 40 mg, polysorbatum 80, carmellosum natricum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, kalii chloridum corresp. kalium 0.39 mg, natrii chloridum, natrii acetas trihydricus, natrii citras dihydricus, natrii hydroxidum aut acidum hydrochloridum, aqua ad iniectabile q.s. ad suspensionem pro 1 ml corresp. natrium 4.27 mg. - visualisation de la vitrectomie - synthetika
triesence 40 mg/ml, suspension injectable
laboratoires alcon - acétonide de triamcinolone - suspension - 40 mg - composition pour 1 ml de suspension injectable > acétonide de triamcinolone : 40 mg - ophtalmologie, anti-inflammatoires, corticostéroïdes
triesence suspension
novartis pharmaceuticals canada inc - acétonide de triamcinolone - suspension - 40mg - acétonide de triamcinolone 40mg - corticosteroids
alluzience solution injectable
future health pharma gmbh - complexus toxini botulinici a et haemagglutinini - solution injectable - complexus toxini botulinici a et haemagglutinini 125 u., histidinum, saccharum, natrii chloridum corresp. natrium 2.156 mg, polysorbatum 80, acidum hydrochloricum q.s. ad ph pro vitro. - zur vorübergehenden verbesserung des erscheinungsbildes von mittelstarken bis starken glabellafalten beim stirnrunzeln bei erwachsenen patienten unter 65 jahren, wenn das ausmass dieser falten eine erhebliche psychische belastung für den patienten darstellt. - biotechnologika
triesence 40 mg/ml 1 vial 1 ml
triesence 40 mg/ml sospensione iniettabile
triesence 40 mg/ml injektionssuspension